3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2/3
1
Status
Completed
4
Unknown
2
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
1
Conditions
Uveal Melanoma
1
Retinal Diseases
1
Myocardial Reperfusion Injury
1
Melanoma
1
Macular Degeneration
1
Choroid Diseases
1
Cardiotoxicity
1
Interventions
Cisplatin
352
Oxaliplatin
262
Capecitabine
258
Radiotherapy
240
Gemcitabine
223
Docetaxel
223
Carboplatin
223
Cyclophosphamide
219
Drug Therapy
218
Paclitaxel
205
apatinib
201
Bevacizumab
195
camrelizumab
190
Fluorouracil
187
sintilimab
133
Blood Specimen Collection
125
Irinotecan
124
Dexamethasone
123
Etoposide
119
Radiosurgery
118
toripalimab
117
Surgical Procedures, Operative
115
pembrolizumab
110
Pemetrexed
108
anlotinib
105
S 1 (combination)
105
Surveys and Questionnaires
101
Leucovorin
101
Nivolumab
98
tislelizumab
96
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
OTHER
×
salicylhydroxamic acid
×
Clear all
NCT02471885
2020-04-15
ERIC-ONC
University College, London
Phase NA
Unknown
128 enrolled
NCT00811200
2009-07-02
TORR
Leiden University Medical Center
Phase 2/3
Unknown
220 enrolled